Benefit of <sup>18</sup>F-fluorocholine PET imaging in parathyroid surgery.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 29372312.
- Also identified by DOI 10.1007/s00330-017-5190-4.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To assess the additional diagnostic value of <sup>18</sup>F-fluorocholine PET imaging in preoperative localization of pathologic parathyroid glands in clinically manifest hyperparathyroidism in case of negative or conflicting ultrasound and scintigraphy results. A retrospective, single-institution study of 26 patients diagnosed with hyperparathyroidism. In cases where ultrasound and scintigraphy failed to detect the location of an adenoma in order to allow a focused surgical approach, an additional <sup>18</sup>F-fluorocholine PET scan was performed and its results were compared with the intraoperative findings. A total of 26 patients underwent <sup>18</sup>F-fluorocholine PET/CT (n = 11) or PET/MRI (n = 15). Adenomas were detected in 25 patients (96.2%). All patients underwent surgery, and the location predicted by PET hybrid imaging was confirmed intraoperatively by frozen section and adequate parathyroid hormone drop after removal. None of the patients needed revision surgery during follow-up. These results demonstrate that <sup>18</sup>F-fluorocholine PET imaging is a highly accurate method to detect parathyroid adenomas even in case of previous localization failure by other imaging examinations. • With <sup>18</sup> F-fluorocholine PET imaging, parathyroid adenomas could be detected in 96.2%. • <sup>18</sup> F-fluorocholine imaging is a highly accurate method to detect parathyroid adenomas. • We encourage its use, where ultrasound fails to detect an adenoma.
Medical subject headings
- Adenoma
- Choline
- Hyperparathyroidism, Primary
- Parathyroid Neoplasms
- Radiopharmaceuticals